Willmann, S., Ince, I., Ahsman, M., Coboeken, K., Zhang, Y., Thelen, K., . . . Lippert, J. (2022). Model‐informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease. CPT: Pharmacometrics & Systems Pharmacology, 11(8), 1111. https://doi.org/10.1002/psp4.12830
Chicago-referens (17:e uppl.)Willmann, Stefan, et al. "Model‐informed Bridging of Rivaroxaban Doses for Thromboprophylaxis in Pediatric Patients Aged 9 Years and Older with Congenital Heart Disease." CPT: Pharmacometrics & Systems Pharmacology 11, no. 8 (2022): 1111. https://doi.org/10.1002/psp4.12830.
MLA-referens (9:e uppl.)Willmann, Stefan, et al. "Model‐informed Bridging of Rivaroxaban Doses for Thromboprophylaxis in Pediatric Patients Aged 9 Years and Older with Congenital Heart Disease." CPT: Pharmacometrics & Systems Pharmacology, vol. 11, no. 8, 2022, p. 1111, https://doi.org/10.1002/psp4.12830.
